WO2013166654A1 - Inhibiteurs de glycosidase perméables et leurs utilisations - Google Patents

Inhibiteurs de glycosidase perméables et leurs utilisations Download PDF

Info

Publication number
WO2013166654A1
WO2013166654A1 PCT/CN2012/075185 CN2012075185W WO2013166654A1 WO 2013166654 A1 WO2013166654 A1 WO 2013166654A1 CN 2012075185 W CN2012075185 W CN 2012075185W WO 2013166654 A1 WO2013166654 A1 WO 2013166654A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
tetrahydro
pyrano
mmol
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2012/075185
Other languages
English (en)
Inventor
Harold G. Selnick
Wenping Li
Eric Hostetler
Kun Liu
Ernest J. Mceachern
Yuanxi Zhou
Zhongyong Wei
Changwei Mu
Yaode Wang
Jiang Chang
Original Assignee
Merck Sharp & Dohme Corp.
Alectos Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp., Alectos Therapeutics Inc. filed Critical Merck Sharp & Dohme Corp.
Priority to PCT/CN2012/075185 priority Critical patent/WO2013166654A1/fr
Priority to EP13787989.6A priority patent/EP2847199B1/fr
Priority to CN201380023214.4A priority patent/CN104395323B/zh
Priority to KR1020147031131A priority patent/KR102108586B1/ko
Priority to CA2871920A priority patent/CA2871920C/fr
Priority to RU2014149183A priority patent/RU2707292C2/ru
Priority to PCT/US2013/039377 priority patent/WO2013169576A1/fr
Priority to JP2015511546A priority patent/JP6178843B2/ja
Priority to US14/399,146 priority patent/US9611275B2/en
Priority to BR112014027724-9A priority patent/BR112014027724B1/pt
Priority to AU2013259892A priority patent/AU2013259892B2/en
Publication of WO2013166654A1 publication Critical patent/WO2013166654A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • NFTs neurofibrillary tangles
  • PHFs paired helical filaments
  • tau Normally tau stabilizes a key cellular network of microtubules that is essential for distributing proteins and nutrients within neurons.
  • tau becomes hyperphosphorylated, disrupting its normal functions, forming PHFs and ultimately aggregating to form NFTs.
  • Six isoforms of tau are found in the human brain. In Alzheimer's disease patients, all six isoforms of tau are found in NFTs, and all are markedly hyperphosphorylated (Goedert et al, Neuron 1992, 8, 159; and Goedert et al, Neuron 1989, 3, 519).
  • O-GlcNAc transferase O-GlcNAc transferase
  • O-GlcNAcase O- linked N-acetylglucosamin-dase
  • HBP hexosamine biosynthetic pathway
  • WO 2006016904 2006 Fulop et al, Journal of Molecular and Cellular Cardiology 2004, 37, 286; Fulop et al, Faseb Journal 2005, 19, A689; and Liu et al, Journal of Molecular and Cellular Cardiology 2007, 42, 177), trauma hemorrhage (Not et al, Faseb Journal 2006, 20, A1471; Yang et al, Shock 2006, 25, 600; and Zou et al, Faseb Journal 2005, 19, A1224), hypervolemic shock (Marchase et al, Circulation 2004, 110, 1099) and calcium paradox
  • O- glycoprotein 2-acetamido-2-deoxy-P-D-glucopyranosidase O-GlcNAcase
  • Family 84 of glycoside hydrolases that includes enzymes from organisms as diverse as prokaryotic pathogens to humans (for the family classification of glycoside hydrolases see Coutinho, P.M. & Henrissat, B.
  • O-GlcNAcase appears to have a role in the etiology of several diseases including type II diabetes (Volleller et al, Proc Natl Acad Sci USA 2002, 99, 5313; and McClain et al, Proc Natl Acad Sci USA 2002, 99, 10695), AD (Griffith, Biochem Biophys Res Commun 1995, 213, 424; Liu et al, Proc Natl Acad Sci USA 2004, 101, 10804; and Yao et al, J.
  • O-GlcNAcase More recently O-GlcNAcase has been cloned (Gao et al, supra), partially characterized (Toleman et al, J Biol Chem 2004) and suggested to have additional activity as a histone acetyltransferase (Toleman et al, supra). However, little was known about the catalytic mechanism of this enzyme.
  • HEXA and HEXB encode enzymes catalyzing the hydrolytic cleavage of terminal ⁇ - ⁇ -acetylglucosamine residues from glycoconjugates.
  • the gene products of HEXA and HEXB predominantly yield two dimeric isozymes, hexosaminidase A and hexosaminidase B, respectively.
  • Hexosaminidase A ( ⁇ ), a heterodimeric isozyme is composed of an a- and a ⁇ -subunit.
  • Hexosaminidase B ( ⁇ ) a homodimeric isozyme, is composed of two ⁇ - subunits.
  • STZ has long been used as a diabetogenic compound because it has a particularly detrimental effect on ⁇ -islet cells (Junod et al, Proc Soc Exp Biol Med 1967, 126, 201). STZ exerts its cytotoxic effects through both the alkylation of cellular DNA (Junod et al, supra; and Bennett et al, Cancer Res 1981, 41, 2786) as well as the generation of radical species including nitric oxide (Kroncke et al, Biol Chem Hoppe Seyler 1995, 376, 179).
  • the resulting DNA strand breakage promotes the activation of poly(ADP-ribose) polymerase (PARP) (Yamamoto et al, Nature 1981, 294, 284) with the net effect of depleting cellular NAD+ levels and, ultimately, leading to cell death (Yamada et al, Diabetes 1982, 31, 749; and Burkart et al, Nat Med 1999, 5, 314).
  • PARP poly(ADP-ribose) polymerase
  • Other investigators have proposed instead that STZ toxicity is a consequence of the irreversible inhibition of O-GlcNAcase, which is highly expressed within ⁇ -islet cells (Konrad et al, supra; and Roos, Proc Assoc Am Physicians 1998, 110, 422).
  • NAG-thiazoline has been found to be a potent inhibitor of family 20 hexosaminidases (Knapp et al, supra; and Mark et al, J Biol Chem 2001, 276, 10330), and more recently, the family 84 O-GlcNAcases (Macauley et al, supra).
  • family 20 hexosaminidases Knapp et al, supra; and Mark et al, J Biol Chem 2001, 276, 10330
  • O-GlcNAcases Macauley et al, supra
  • PUGNAc is another compound that suffers from the same problem of lack of selectivity, yet has enjoyed use as an inhibitor of both human O-GlcNAcase (Dong et al, supra; and Haltiwanger et al, J Biol Chem 1998, 273, 3611) and the family 20 human ⁇ - hexosaminidases (Miller et al, Development 1993, 118, 1279).
  • This molecule developed by Vasella and coworkers, was found to be a potent competitive inhibitor of the ⁇ -N-acetyl- glucosaminidases from Canavalia ensiformis, Mucor rouxii, and the ⁇ -hexosaminidase from bovine kidney (Horsch et al, supra). It has been demonstrated that administration of PUGNAc in a rat model of trauma hemorrhage decreases circulating levels of the pro-inflammatory cytokines TNF a and IL-6 (Zou et al, Shock 2007, 27, 402). It has also been shown that administration of PUGNAc in a cell-based model of lymphocyte activation decreases production of the cytokine IL- 2 (Huang et al, Cellular Immunology 2007, 245, 1). Recent studies have indicated that
  • PUGNAc can be used in an animal model to reduce myocardial infarct size after left coronary artery occlusion (U.J.G. Conference, in US/Japan Gylco 2004 Conference, Honolulu, Hawaii, 2004).
  • O-GlcNAc an inhibitor of O-GlcNAcase
  • a rat model of trauma hemorrhage improves cardiac function (Zou et al, Shock 2007, 27, 402; and Zou et al, Faseb Journal 2006, 20, A1471).
  • O-GlcNAc levels by treatment with PUGNAc in a cellular model of ischemia/reperfusion injury using neonatal rat ventricular myocytes improved cell viability and reduced necrosis and apoptosis compared to untreated cells (Champattanachai et al, American Journal of Physiology-Cell Physiology 2007, 292, CI 78).
  • Noninvasive nuclear imaging techniques can be used to obtain basic and diagnostic information about the physiology and biochemistry of a variety of living subjects including experimental animals, normal humans and patients. These techniques rely on the use of sophisticated imaging instrumentation that is capable of detecting radiation emitted from radiotracers administered to such living subjects. The information obtained can be reconstructed to provide planar and tomographic images that reveal distribution of the radiotracer as a function of time. Use of appropriately designed radiotracers can result in images which contain information on the structure, function and most importantly, the physiology and biochemistry of the subject. Much of this information cannot be obtained by other means.
  • radiotracers used in these studies are designed to have defined behaviors in vivo which permit the determination of specific information concerning the physiology or biochemistry of the subject or the effects that various diseases or drugs have on the physiology or biochemistry of the subject.
  • radiotracers are available for obtaining useful information concerning such things as cardiac function, myocardial blood flow, lung perfusion, liver function, brain blood flow, brain regional distribution and function.
  • compounds can be labeled with either positron-or gamma-emitting radionuclides.
  • positron emitting (PET) radionuclides are n C, 18 F, 15 0 and 13 N, all of which are accelerator produced, and have half-lives of 20, 110, 2 and 10 minutes, respectively. These short half-lives endow a number of advantages to their use as tracers to probe biological processes in vivo using PET. Since the half-lives of these
  • radionuclides are so short, it is only feasible to use them at institutions that have an accelerator on site or very close by for their production, thus limiting their use.
  • a small amount of radiotracer is administered to the experimental animal, normal human or patient being tested.
  • the radiotracer then circulates in the blood of the subject and may be absorbed in certain tissues.
  • the radiotracer may be preferentially retained in some of these tissues because of specific enzymatic conversion or by specific binding to macromolecular structures such as proteins.
  • the amount of radiotracer is then non-invasively assessed in the various tissues in the body. The resulting data are analyzed to provide quantitative spatial information of the in vivo biological process for which the tracer was designed.
  • PET gives pharmaceutical research investigators the capability to assess biochemical changes or metabolic effects of a drug candidate in vivo for extended periods of time, and PET can be used to measure drug distribution, thus allowing the evaluation of the pharmacokinetics and pharmacodynamics of a particular drug candidate under study.
  • PET tracers can be designed and used to quantitate the presence of binding sites in tissues. Consequently, interest in PET tracers for drug development has been expanding based on the development of isotopically labeled biochemicals and
  • Noninvasive nuclear imaging techniques such as PET have been particularly important in providing the ability to study neurological diseases and disorders, including stroke, Parkinson's disease, epilepsy, cerebral tumors and Alzheimer's disease.
  • Alzheimer's disease is the most common form of dementia.
  • a PET radiotracer specific O-GlcNAcase would provide a powerful tool in demonstrating target engagement and pharmacodynamic activity and determining optimal doses in preclinical evaluation and clinical trials.
  • Compounds disclosed herein as inhibitors of O- GlcNAcase possess both high potency and high permeability, and thus are useful in the treatment of diseases, disorders, or conditions that would benefit from the inhibition of O-GlcNAcase and reducing NFTs.
  • the invention also provides compounds which when radiolabeled are useful as PET radiotracers for imaging of O-GlcNAcase in vivo.
  • the invention is directed to compounds which are useful as inhibitors of O- GlcNAcase and methods for the use of such O-GlcNAcase inhibitors and pharmaceutical formulations comprising these inhibitors for treatment of certain disorders, including Alzheimer's disease.
  • the invention is also concerned with such radiolabeled O-GlcNAcase inhibitors for use in binding studies and diagnostic imaging of O-GlcNAcase in mammals.
  • One or more means at least one.
  • Subject means an animal, such as a mammal, e.g., mouse, rat, horse, cow, sheep, goat, dog, cat, pig, monkey, or a human; or avian species, e.g., chicken.
  • compound or “compounds” refers to the compounds discussed herein and includes precursors and derivatives of the compounds, including acyl-protected derivatives, and pharmaceutically acceptable salts of the compounds, precursors, and derivatives.
  • the invention also includes prodrugs of the compounds, pharmaceutical compositions including the compounds and a pharmaceutically acceptable carrier, and pharmaceutical compositions including prodrugs of the compounds and a pharmaceutically acceptable carrier.
  • Alkyl refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing no unsaturation and including, for example, from one to ten carbon atoms, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, the alkyl group may be optionally substituted by one or more substituents as described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkyl group.
  • alkenyl refers to a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one double bond and including, for example, from two to ten carbon atoms, such as 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms, and which is attached to the rest of the molecule by a single bond or a double bond.
  • the alkenyl group may be optionally substituted by one or more substituents as described herein. Unless stated otherwise specifically herein, it is understood that the substitution can occur on any carbon of the alkenyl group.
  • Alkoxy means an -O-(Cl-10)alkyl or alkenyl group in which the alkyl or alkenyl group is as previously described.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy and n-butoxy.
  • the bond to the parent moiety is through the ether oxygen.
  • Cycloalkyl refers to a stable monovalent monocyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, having for example from 3 to 6 carbon atoms, and which is saturated and attached to the rest of the molecule by a single bond. Unless otherwise stated specifically herein, the term “cycloalkyl” is meant to include cycloalkyl groups which are optionally substituted as described herein.
  • Solvate means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate” encompasses both solution-phase and isolatable solvates. Non- limiting examples of suitable solvates include ethanolates, methanolates, and the like. A “hydrate” is a solvate wherein the solvent molecule(s) is/are H 2 0.
  • In vivo hydrolysable precursors means an in vivo hydrolysable (or cleavable) ester of a compound of Formula I, la, lb, II, Ila and lib that contains a carboxy or a hydroxy group, e.g., amino acid esters, Ci -6 alkoxymethyl esters like methoxymethyl; Ci -6
  • alkanoyloxymethyl esters like pivaloyloxymethyl; C 3- 8cycloalkoxycarbonyloxy, Ci -6 alkyl esters like acetyl, 1-cyclohexylcarbonyloxyethyl, acetoxymethoxy, or phosphoramidic cyclic esters.
  • Radionuclides i.e. “detectable isotopes”
  • n C, 13 C, 14 C, 18 F , 2 H and 3 H e.g., n C, 13 C, 14 C, 18 F , 2 H and 3 H.
  • Effective amount include amounts that enable measuring/imaging of O- GlcNAcase in vivo (i.e., diagnostically effective amount), that yield acceptable toxicity and bioavailability levels for pharmaceutical use and/or inhibit or prevent cell degeneration and toxicity associated with NFTs (i.e., therapeutically effective amount).
  • This invention provides compounds of the Formula (I)
  • each R is independently H or C(0)CH 3 ;
  • R 1 and R 2 are independently (a) hydrogen, (b) Cl-6alkyl optionally substituted with 1 to 3 substituents selected from F, -OH, -OCH 3 and -CH 3 , or (c) Cl-6alkoxy optionally substituted with 1 to 3 substituents selected from F, -OH, -OCH 3 and -CH 3 ; or
  • R and R2 may be joined together with the nitrogen atom to which they are attached to form azetidine, pyrrolidine, piperidine or isoxazolidine;
  • R 3 is Cl-lOalkyl optionally substituted with 1 to 3 fluoro;
  • R 4 is hydrogen or Cl-lOalkyl optionally substituted with phenyl
  • R 5 is (A) Cl-6alkyl optionally substituted with one substituent selected from
  • R, R 1 , R 2 , R 3 , R 4 and R 5 have the definitions as defined in the previous embodiments for the compounds of Formula (I).
  • the compounds of the invention are highly potent (see Table 2 of the Examples), selective and permeable inhibitors of O-GlcNAcase.
  • the compounds of the present invention also possess enhanced permeability (see Table 3 in the Examples) when compared to the permeability of structurally compounds described in PCT/USl 1/059668, filed November 8, 2011 (see Table 4).
  • the compounds of the invention are useful in providing treatment of neurodegenerative diseases or conditions associated with FT formation such as Alzheimer's disease and related tauopathies such as amyotrophic lateral sclerosis, glaucoma, schizophrenia, cancer and other diseases and disorders as indicated below.
  • isotopically labeled e.g., with a positron emitting
  • radionuclide such as n C
  • certain specifically disclosed compounds are also useful as positron emission tomographic (PET) tracers for imaging O-GlcNAcase in the brain of living humans and experimental animals, i.e., measuring central occupancy of O-GlcNAcase.
  • PET positron emission tomographic
  • Imaging of O- GlcNAcase in turn can aid in defining clinically efficacious doses of an unlabeled O-GlcNAcase inhibitor and provide information useful in selecting a drug candidate for clinical development.
  • one or more of the compounds according to the invention exhibit enhanced permeability. Permeability can be assessed using a variety of standard experimental techniques, including without limitation in situ perfusion, ex vivo tissue diffusion, in vitro cell monolayers (e.g. Caco-2 cells, MDCK cells, LLC-PK1 cells), and artificial cell membranes (e.g. PAMPA assay); suitable techniques for measuring effective permeability (P eff ) or apparent peameability (P app ) are reviewed for example by Volpe in The AAPS Journal, 2010, 12(4), 670-678. In some embodiments, one or more of the compounds according to the invention show enhanced permeability when tested in one or more of these assays for determining P eff or P ap p.
  • a compound that exhibits enhanced permeability exhibits greater oral absorption. In some embodiments, a compound that exhibits enhanced permeability exhibits greater brain penetration when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability achieves higher brain concentrations when administered in vivo. In some embodiments, a compound that exhibits enhanced permeability exhibits a higher brain/plasma concentration ratio when administered in vivo.
  • "enhanced permeability” means an increase in measured P eff or P app by any value between 10% and 100%, or of any integer value between 10% and 100%, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or over 100%, or an increase by 1-fold, 2-fold, or 3 -fold, or more, as compared to a suitable reference compound disclosed in for example WO 2006/092049 or WO 2008/025170.
  • a suitable reference compound may be, for example, (3aR,5R,6S,7R,7aR)-5- (hydroxymethyl)-2-propyl-5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazole-6,7-diol, or
  • “enhanced permeability” means a P ap p value greater than 2 x 10 "6 cm/s in the assay described below for determination of P app in LLC-PK1 cells. In some embodiments, “enhanced permeability” means a P app value greater than 1 x 10 "6 cm/s in the assay described below for determination of P app in LLC-PK1 cells. In alternative embodiments, “enhanced permeability” means a P app value in the range 2 x 10 " cm/s to 30 x 10 " cm/s in the assay described below for determination of P app in LLC-PK1 cells.
  • a compound according to the invention exhibits superior selectivity in inhibiting an O-GlcNAcase.
  • one or more of the compounds according to the invention are more selective for an O-GlcNAcase over a ⁇ -hexosaminidase.
  • one or more of the compounds selectively inhibit the activity of a mammalian O-GlcNAcase over a mammalian ⁇ -hexosaminidase.
  • a selective inhibitor of an O-GlcNAcase does not substantially inhibit a ⁇ -hexosaminidase.
  • the ⁇ -hexosaminidase is a mammalian ⁇ -hexosaminidase, such as a rat, mouse or human ⁇ - hexosaminidase.
  • a compound that "selectively" inhibits an O-GlcNAcase is a compound that inhibits the activity or biological function of an O-GlcNAcase, but does not substantially inhibit the activity or biological function of a ⁇ -hexosaminidase.
  • a selective inhibitor of an O-GlcNAcase selectively inhibits the cleavage of 2-acetamido-2-deoxy ⁇ - D-glucopyranoside (O-GlcNAc) from polypeptides.
  • a selective inhibitor of an O-GlcNAcase selectively binds to an O-GlcNAcase.
  • a selective inhibitor of an O-GlcNAcase inhibits hyperphosphorylation of a tau protein and/or inhibits formations of FTs.
  • inhibits means a decrease by any value between 10% and 90%, or of any integer value between 30% and 60%, or over 100%, or a decrease by 1-fold, 2-fold, 5-fold, 10-fold or more. It is to be understood that the inhibiting does not require full inhibition.
  • a selective inhibitor of an O-GlcNAcase elevates or enhances O-GlcNAc levels e.g., O-GlcNAc-modified polypeptide or protein levels, in cells, tissues, or organs (e.g., in brain, muscle, or heart (cardiac) tissue) and in animals.
  • O-GlcNAc levels e.g., O-GlcNAc-modified polypeptide or protein levels
  • O-GlcNAc-modified polypeptide or protein levels in cells, tissues, or organs (e.g., in brain, muscle, or heart (cardiac) tissue) and in animals.
  • elevating or “enhancing” is meant an increase by any value between 10% and 90%, or of any integer value between 30% and 60%, or over 100%, or an increase by 1-fold, 2-fold, 5 -fold, 10- fold, 15-fold, 25-fold, 50-fold, 100-fold or more.
  • a selective inhibitor of an O-GlcNAcase exhibits a selectivity ratio, as described herein, in the range 10 to 100000, or in the range 100 to 100000, or in the range 1000 to 100000, or at least 10, 20, 50, 100, 200, 500, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 6000, 7000, 10,000, 25,000, 50,000, 75,000, or any value within or about the described range.
  • R 1 and R 2 are independently hydrogen or Cl-5, Cl-4, Cl-3, or Cl-2alkyl or -CH 3 , the alkyl being optionally substituted with 1 to 3 of the aforementioned substituents.
  • R 3 is CI -9, CI -8, CI -7, Cl-6, Cl-5, Cl-4, Cl-3, Cl-2alkyl optionally substituted with 1 to 3 fluoro.
  • R 3 is methyl or trifluoromethyl.
  • R 4 is hydrogen. In another embodiment of the compounds of Formula (I), R 4 is Cl-6, Cl-5, Cl-4, Cl-3, Cl-2alkyl or -CH 3 .
  • R 4 is -CH 3 .
  • R 4 is ethyl optionally substituted with phenyl.
  • R 5 is Cl-5, Cl-4, Cl-3, Cl-2alkyl or -CH 3 optionally substituted with one of the aforementioned substituents.
  • the alkyl of R 5 is substituted with C5-or C6-cycloalkyl.
  • the alkyl of R 5 is optionally substituted with pyridinyl, wherein the pyridinyl is optionally substituted with -CH 3 .
  • the alkyl of R 5 is optionally substituted with phenyl, wherein the phenyl is optionally substituted with 1, 2 or 3 of the aforementioned substituents.
  • the compounds are of Formula (la) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof:
  • the compounds are of Formula (lb) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof:
  • Formula (lb), and R, R 1 , R 2 , R 3 , R 4 and R 5 have the definitions as defined in the previous embodiments for the compounds of Formula (I).
  • R 3 is methyl or trifluoromethyl
  • R 4 is hydrogen
  • R 5 is Cl-6alkyl optionally substituted with one substituent selected from
  • R 3 is methyl or trifluoromethyl
  • R 4 is hydrogen
  • R 5 is phenyl optionally substituted with one substituent selected from (1) -N0 2 , (2) -NH 2 , (3) fiuoro, (4) Cl-6alkyl optionally substituted with fiuoro and (5) Cl-6alkoxy optionally substituted with fiuoro.
  • R 3 is methyl or trifluoromethyl;
  • R 4 is hydrogen; and
  • R 5 is pyridinyl optionally substituted with one substituent selected from 1) fluoro, 2) Cl-6alkyl optionally substituted with fluoro and 3) Cl-6alkoxy optionally substituted with fluoro.
  • the compound is selected from the group consisting of Examples 1-11, 20-111, 118, 119 and 120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, the compound is selected from the group consisting of Examples 1-11, 20-111, 118, 119 and 120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, the compound is selected from the group consisting of Examples 1-11, 20-111, 118, 119 and 120 or a
  • This invention also provides compounds of Formula (II):
  • each R is independently H or C(0)CH 3 ;
  • R 1 and R 2 are independently (a) hydrogen, (b) Cl-6alkyl optionally substituted with 1 to 3 substituents selected from F, -OH, -OCH 3 and -CH 3 , or (c) Cl-6alkoxy optionally substituted with 1 to 3 substituents selected from F, -OH, -OCH 3 and -CH 3 ; or
  • R and R2 may be joined together with the nitrogen atom to which they are attached to form azetidine, pyrrolidine, piperidine or isoxazolidine;
  • R 3 is Cl-lOalkyl optionally substituted from 1 to 3 fluoro;
  • R 4 and R 5 are independently hydrogen or CI -6 alkyl
  • R 6 is hydrogen, Cl-6alkyl or C3-6cycloalkyl.
  • R 1 and R 2 are independently hydrogen, or CI -3 alkyl or -CH 3 ;
  • R 3 is -CH 3 or -CF 3 ;
  • R 4 is hydrogen
  • R 5 is hydrogen or -CH 3 ;
  • R 6 is -CH 3 , -CH 2 CH 3 or cyclopentyl.
  • Formula (II) above may also be represented alternatively as follows:
  • R 1 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, wherein R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the definitions as defined in the previous embodiments for the compounds of Formula (II).
  • the compounds are of Formula (Ila) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof:
  • R, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the definitions as defined in the previous embodiments for the compounds of Formula (II).
  • the compounds are of Formula (lib) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof:
  • the compounds are selected from the group consisting of Examples 12-19, 112-115 and 116 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.
  • the compounds of the Formulas (I), (la), (lb), (II), (Ha), and (lib) also include isotopically labeled compounds.
  • Suitable radionuclides i.e. "detectable isotopes” that may be incorporated in compounds of the invention include but are not limited to n C, 13 C, 14 C, 18 F, 2 H and 3 H, and preferably n C.
  • the isotopically labeled compounds of the invention need only to be enriched with a detectable isotope to, or above, the degree which allows detection with a technique suitable for the particular application.
  • the radionuclide that is incorporated in the instant radiolabeled compounds will depend on the specific application of that radiolabeled compound.
  • the compounds of Formula (I) are selected from the group consisting of Examples 118-120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, and in further embodiments these compounds are isotopically labeled with n C.
  • the compounds of the present invention may have asymmetric centers, chiral axes and chiral planes, and occur as racemates, racemic mixtures, and as individual diastereomers, with all possible isomers, including optical isomers, being included in the present invention. (See E.L. Eliel and S.H. Wilen Stereochemistry of Carbon Compounds (John Wiley and Sons, New York 1994), in particular pages 1119-1190).
  • Salts of the compounds of the invention will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
  • suitable “pharmaceutically acceptable salts” refers to salts prepared form pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as arginine, betaine caffeine, choline, ⁇ , ⁇ 1 - dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine tripropylamine, tromethamine and the
  • Salts of the compounds which are in basic form may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids.
  • Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric and tartaric acids.
  • the compounds according to the invention have pharmacological properties, i.e., the compounds can selectively inhibit O-GlcNAcase and exhibit both high potency and high permeability, they may be useful in the treatment or prevention of neurodegenerative diseases, e.g., Alzheimer's disease and other neurodegenerative diseases or conditions and related tauopathies.
  • Related tauopathies include but are not limited to Amyotrophic lateral sclerosis, Amyotrophic lateral sclerosis with cognitive impairment, Argyrophilic grain dementia, Bluit disease,
  • Corticobasal degeneration Dementia pugilistica, Diffuse neurofibrillary tangles with calcification, Down's syndrome, Familial British dementia, Familial Danish dementia, Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), Gerstmann-Straussler-Scheinker disease, Guadeloupean parkinsonism, Hallevorden-Spatz disease (neurodegeneration with brain iron accumulation type 1), Multiple system atrophy, Myotonic dystrophy, Niemann-Pick disease (type C), Pallido-ponto-nigral degeneration, Parkinsonism-dementia complex of Guam, Pick's disease, Post-encephalitic parkinsonism , Prion diseases (including Creutzfeldt- Jakob Disease, Variant Creutzfeldt- Jakob Disease, Fatal Familial Insomnia, and Kuru), Progressive supercortical gliosis, Progressive supranuclear palsy, Richardson's syndrome
  • the compounds of the invention may also be useful for treatment of neurodegenerative diseases, including Parkinson's disease and Huntington's disease.
  • Other conditions that may be treated are those triggered, affected, or in any other way correlated with levels of O-GlcNAc post-translational protein modification. It is expected that the compounds of this invention may be useful for the treatment of such conditions and in particular, but not limited to, the following for which a association with O-GlcNAc levels on proteins has been established: graft rejection, in particular but not limited to solid organ transplants, such as heart, lung, liver, kidney, and pancreas transplants (e.g.
  • kidney and lung allografts cancer, in particular but not limited to cancer of the breast, lung, prostate, pancreas, colon, rectum, bladder, kidney, ovary; as well as non-Hodgkin's lymphoma and melanoma; epilepsy, pain, fibromyalgia, or stroke, e.g., for neuroprotection following a stroke.
  • Compounds that selectively inhibit O-GlcNAcase activity may also be used for the treatment of diseases that are associated with inflammation, including but not limited to, of an inflammatory disease, an allergy, asthma, allergic rhinitis, hypersensitivity lung diseases, hypersensitivity pneumonitis, eosinophilic pneumonias, delayed-type hypersensitivity,
  • interstitial lung disease ILD
  • idiopathic pulmonary fibrosis ILD associated with rheumatoid arthritis
  • systemic lupus erythematosus ankylosing spondylitis
  • systemic sclerosis Sjogren's syndrome
  • polymyositis or dermatomyositis systemic anaphylaxis or hypersensitivity response
  • drug allergy insect sting allergy
  • autoimmune disease rheumatoid arthritis
  • psoriatic arthritis multiple sclerosis
  • Guillain-Barre syndrome systemic lupus erythematosus
  • myastenia gravis glomerulonephritis
  • autoimmune thyroiditis graft rejection, allograft rejection, graft- versus-host disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis
  • spondyloarthropathy scleroderma
  • psoriasis T-cell mediated psoriasis
  • inflammatory dermatosis dermatitis, eczema
  • atopic dermatitis allergic contact dermatitis
  • urticaria vasculitis
  • necrotizing cutaneous, and hypersensitivity vasculitis
  • eosinphilic myotis eosiniphilic fasciitis, solid organ transplant rejection, heart transplant rejection, lung transplant rejection, liver transplant rejection, kidney transplant rejection, pancreas transplant rejection, kidney allograft, lung allograft, epilepsy, pain, fibromyalgia, stroke, and neuroprotection.
  • compounds that affects levels of protein O-GlcNAc modification may be used for the treatment of diseases associated with immunosuppression, such as in individuals undergoing chemotherapy, radiation therapy, enhanced wound healing and burn treatment, therapy for autoimmune disease or other drug therapy (e.g., corticosteroid therapy) or combination of conventional drugs used in the treatment of autoimmune diseases and
  • the compounds of this invention may also be useful in the treatment of conditions associated with tissue damage or stress, stimulating cells, or promoting differentiation of cells. Accordingly, in some embodiments, a compound of this invention may be used to provide therapeutic benefit in a variety of conditions or medical procedures involving stress in cardiac tissue, including but not limited to: ischemia; hemorrhage; hypovolemic shock; myocardial infarction; an interventional cardiology procedure; cardiac bypass surgery; fibrinolytic therapy; angioplasty; and stent placement.
  • the compounds of the invention may be used to treat animals, including mice, rats, horses, cattle, sheep, dogs, cats, and monkeys. However, compounds of the invention can also be used in other organisms, such as avian species (e.g., chickens). The compounds of the invention may also be effective for use in humans.
  • the term "subject” or alternatively referred to herein as "patient” is intended to be referred to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment. However, the compounds, methods and pharmaceutical compositions of the present invention may be used in the treatment of animals.
  • a "subject” may be a human, non-human primate, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc.
  • the subject may be suspected of having or at risk for having a condition requiring modulation of O-GlcNAcase activity.
  • Huntington's disease, Parkinson's disease, mild cognitive impairment, neuropathy (including peripheral neuropathy, autonomic neuropathy, neuritis, diabetic neuropathy) and cancer is provided, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition of the compound, salt or ester.
  • a compound of the invention or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, or a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof is administered concurrently, simultaneously, sequentially or separately with another pharmaceutically active compound or compounds used in Alzheimer's therapies including for example donepezil, memantine, tacrine and equivalents and pharmaceutically active isomer(s) and metabolite(s) thereof.
  • a compound according to the invention, or for use according to the invention may be provided in combination with any other active agents or pharmaceutical compositions where such combined therapy is useful to modulate O-GlcNAcase activity, for example, to treat neurodegenerative, inflammatory, cardiovascular, or immunoregulatory diseases, or any condition described herein.
  • a compound according to the invention, or for use according to the invention may be provided in combination with one or more agents useful in the prevention or treatment of Alzheimer's disease. Examples of such agents include, without limitation,
  • acetylcholine esterase inhibitors such as Aricept® (Donepezil), Exelon®
  • NMDA receptor antagonists such as Namenda® (Axura®, Akatinol®, Ebixa®,
  • gamma- seer etase inhibitors and/or modulators such as FlurizanTM (Tarenflurbil, MPC- 7869, R-flurbiprofen), LY450139, MK 0752, E2101, BMS-289948, BMS-299897, BMS- 433796, LY-411575, GSI-136, etc.;
  • beta-secretase inhibitors such as ATG-Z1, CTS-21166, MK-8931, etc.
  • alpha- seer etase activators such as NGX267, etc;
  • amyloid- ⁇ aggregation and/or fibrillization inhibitors such as AlzhemedTM (3 APS,
  • Tramiprosate 3-amino-l-propanesulfonic acid
  • AL-108 3-amino-l-propanesulfonic acid
  • AL-208 3-amino-l-propanesulfonic acid
  • AL-108 3-amino-l-propanesulfonic acid
  • AL-208 3-amino-l-propanesulfonic acid
  • AL-108 3-amino-l-propanesulfonic acid
  • AL-208 3-amino-l-propanesulfonic acid
  • AL-208 3-amino-l-propanesulfonic acid
  • AZD-103 3-amino-l-propanesulfonic acid
  • PBT2 Cereact
  • ONO-2506PO 2-amino-l-propanesulfonic acid
  • tau aggregation inhibitors such as methylene blue, etc.
  • microtubule stabilizers such as AL-108, AL-208, paclitaxel, etc.
  • RAGE inhibitors such as TTP488, etc.
  • 5-HTla receptor antagonists such as Xaliproden, Lecozotan, etc.
  • 5-HT4 receptor antagonists such as PRX-03410, etc.
  • kinase inhibitors such as SRN-003-556, amfurindamide, LiCl, AZD1080, NP031112, SAR-502250, etc.;
  • humanized monoclonal anti- ⁇ antibodies such as Bapineuzumab (AAB-001),
  • amyloid vaccines such as AN- 1792, ACC-001, etc.
  • neuroprotective agents such as Cerebrolysin, AL-108, AL-208, Huperzine A, etc.;
  • L-type calcium channel antagonists such as MEM- 1003, etc.
  • nicotinic receptor antagonists such as AZD3480, GTS-21, etc.
  • nicotinic receptor agonists such as MEM 3454, Nefiracetam, etc.
  • peroxisome proliferator-activated receptor (PPAR) gamma agonists such as Avandia® (Rosglitazone), etc.;
  • PDE4 inhibitors such as MK-0952, etc.
  • hormone replacement therapy such as estrogen (Premarin), etc.
  • monoamine oxidase (MAO) inhibitors such as NS2330, Rasagiline (Azilect®), TVP-1012, etc.
  • AMP A receptor modulators such as Ampalex (CX 516), etc.
  • nerve growth factors or NGF potentiators such as CERE-110 (AAV-NGF), T-588, T- 817MA, etc.;
  • agents that prevent the release of luteinizing hormone (LH) by the pituitary gland such as leuoprolide (VP-4896), etc.;
  • GABA receptor modulators such as AC-3933, NGD 97-1, CP-457920, etc.;
  • benzodiazepine receptor inverse agonists such as SB-737552 (S-8510), AC-3933, etc.;
  • noradrenaline-releasing agents such as T-588, T-817MA, etc.
  • the O-GlcNAcase inhibitors will generally be administered orally.
  • compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. This dosage regimen may be adjusted to provide the optimal therapeutic response. It will be understood, however, that the specific dose level and frequency of dosage for any particular subject may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
  • compositions including the compounds of the invention, or for use according to the invention, are contemplated as being within the scope of the invention.
  • composition as used herein is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • Such term in relation to pharmaceutical composition is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients.
  • the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and one or more pharmaceutically acceptable carriers.
  • compositions of this invention may be used in the form of a pharmaceutical preparation, for example, in solid, semisolid or liquid form, which contains one or more of the compounds of the present invention, as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for external, enteral or parenteral applications.
  • the active ingredient may be compounded, for example, with the usual non-toxic,
  • pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use.
  • the carriers which can be used are water, glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.
  • the active object compound is included in the pharmaceutical composition in an amount sufficient to produce the desired effect upon the process or condition of the disease.
  • liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solution, suitably flavoured syrups, aqueous or oil suspensions, and emulsions with acceptable oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, or with a solubilizing or emulsifying agent suitable for intravenous use, as well as elixirs and similar pharmaceutical vehicles.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
  • the invention also provides a method for diagnostic imaging (i.e., measuring central occupancy) of O-GlcNAcase in a mammal, e.g., a rodent, non-human primate or human, which comprises administering to the mammal in need of such diagnostic imaging an effective amount of the isotopically labeled compound selected from Examples 118-120 or a
  • the invention also provides a method for diagnostic imaging of the brain in a mammal which comprises administering to the mammal in need of such diagnostic imaging an effective amount of the isotopically labeled compound selected from Examples 118-120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.
  • the invention also provides a method for the detection or quantification of O- GlcNAcase in mammalian tissue, e.g., brain, the method comprising contacting the mammalian tissue in which such detection is desired with an effective amount of the isotopically labeled compound selected from Examples 118-120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.
  • the invention is also, in part, to develop radiolabeled O-GlcNAcase inhibitors that would be useful not only in traditional exploratory and diagnostic imaging applications, but also be useful in assays, both in vitro and in vivo for labeling the O-GlcNAcase enzyme and for competing with unlabeled O-GlcNAcase inhibitors.
  • radiolabeled O-GlcNAcase inhibitors that would be useful not only in traditional exploratory and diagnostic imaging applications, but also be useful in assays, both in vitro and in vivo for labeling the O-GlcNAcase enzyme and for competing with unlabeled O-GlcNAcase inhibitors.
  • a method of determining the plasma concentration/occupancy relationship of an unlabeled O-GlcNAcase inhibitor comprises administering to the subject such as a human an effective amount of an isotopically labeled compound selected from Examples 118-120 or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof.
  • radionuclides that may be incorporated in the instant compounds include but are not limited to n C, 13 C, 14 C, 18 F and 3 H, and preferably n C.
  • the mammal is e.g., a rodent, a non-human primate or a human.
  • diagnostic imaging of O-GlcNAcase is carried out by performing PET imaging, magnetic resonance imaging, or autoradiography.
  • Isotopically labeled compounds of the invention are potentially useful for diagnostic imaging, basic research, and radiotherapeutic applications.
  • diagnostic imaging and radiotherapeutic applications include determining the location, the relative activity or abundance of O-GlcNAcase, radioimmunoassay of O-GlcNAcase, and autoradiography to determine the distribution of O-GlcNAcase in the brain of a mammal.
  • these isotopically labeled compounds in particular the compounds of Examples 118-120 or pharmaceutically acceptable salts, solvate or in vivo hydrolysable esters thereof, when labeled with the positron emitting radionuclide, n C, are useful for PET imaging of O-GlcNAcase in the brain of living humans and experimental animals.
  • These isotopically labeled compounds may be used as research tools to study the interaction of unlabeled O-GlcNAcase inhibitors with O-GlcNAcase in vivo via competition between the unlabeled drug and the radiolabeled compound for binding to the enzyme.
  • the radiolabeled O-GlcNAcase inhibitors may be used to help define a clinically efficacious dose of an O-GlcNAcase inhibitor.
  • the radiolabeled O-GlcNAcase inhibitors can be used to provide information that is useful for choosing between potential drug candidates for selection for clinical
  • the radiolabeled O-GlcNAcase inhibitors may also be used to study the regional distribution and concentration of O-GlcNAcase in the living human brain, as well as the brain of living experimental animals and in tissue samples.
  • the radiolabeled O-GlcNAcase inhibitors may also be used to study disease or pharmacologically related changes in O-GlcNAcase
  • PET tracers such as the present radiolabeled O-GlcNAcase inhibitors which can be used with currently available PET technology to obtain the following information: relationship between level of receptor occupancy by candidate O-GlcNAcase inhibitors and clinical efficacy in subjects; dose selection for clinical trials of O-GlcNAcase prior to initiation of long term clinical studies; comparative potencies of structurally novel O-GlcNAcase inhibitors; investigating the influence of O-GlcNAcase inhibitors on in vivo affinity and density during the treatment of clinical targets with O-GlcNAcase inhibitors and other agents; changes in the density and distribution of O-GlcNAcase during e.g. Alzheimer's disease in its active stages, during effective and ineffective treatment and during remission; and changes in O-GlcNAcase expression and distribution in CNS disorders, imaging neurodegenerative disease where O-GlcNAcase are involved; and the like.
  • the radiolabeled compounds of the invention also have utility in diagnostic imaging with respect to a variety of neurological and psychiatric disorders associated with NFT formation including Alzheimer's disease and related tauopathies as described above, glaucoma,
  • the radiolabeled compounds may be administered to mammals, preferably humans, in a pharmaceutical composition, either alone or, preferably, in combination with one or more pharmaceutically acceptable carriers or diluents, optionally with known adjuvants, such as alum, in a pharmaceutical composition, according to standard pharmaceutical practice.
  • a pharmaceutical composition can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.
  • radionuclides are generally administered via intravenous injection within less than one hour of their synthesis. This is necessary because of the short half-life of the radionuclides involved (20 and 110 minutes for n C and 18 F, respectively).
  • the amount required for diagnostic imaging will normally be determined by the prescribing physician with the dosage generally varying according to the age, weight, and response of the individual subject, as well as the quantity of emission from the radionuclide.
  • an effective amount will be the amount of compound sufficient to produce emissions in the range of from about 1 -10 mCi.
  • administration occurs in an amount of radiolabeled compound of between about 0.005 ⁇ g/kg of body weight to about 50 g/kg of body weight per day, preferably of between 0.02 g/kg of body weight to about 7 g/kg of body weight.
  • a particular analytical dosage that comprises the instant composition includes from about 0.5 ⁇ g to about 100 ⁇ g of the isotopically labeled compound.
  • the dosage comprises from about 1 ⁇ g to about 50 ⁇ g of the isotopically labeled compound.
  • the following illustrative procedure may be utilized when performing PET imaging studies on subjects in the clinic.
  • the subject undergoes a baseline scan as described below, after which the subject is premedicated with unlabeled O-GlcNAcase inhibitor for the desired time prior to the day of the experiment and is fasted for at least 12 hours allowing water intake ad libitum.
  • a 20 G two inch venous catheter is inserted into the contralateral ulnar vein for radiotracer administration.
  • the subject is positioned in the PET camera and a tracer dose of [ 15 0] H 2 0 administered via i.v. catheter.
  • the image thus obtained is used to insure that the subject is positioned correctly to include the brain or other areas of interest.
  • the isotopically labeled O-GlcNAcase inhibitor e.g., compound labeled with n C ( ⁇ 10 mCi)
  • n C ⁇ 10 mCi
  • regions of interest are drawn on the reconstructed image including, e.g. the brain and the central nervous system. These regions are used to generate time activity curves obtained in the absence of O-GlcNAcase inhibitor or in the presence of the clinical candidate at the various infusion doses examined. Data are expressed as radioactivity per unit time per unit volume ⁇ Ci/cc/mCi injected dose). Inhibition curves are generated from the data obtained in a region of interest obtained starting at 70 minutes post-injection of radiotracer. At this time, clearance of non-specific binding has reached steady state. The ID 50 values are obtained by curve fitting the dose-rate/inhibition curves with equation iii:
  • B is the%-Dose/g of radiotracer in tissues for each dose of clinical candidate
  • Ao is the specifically bound radiotracer in a tissue in the absence of a O-GlcNAcase inhibitor
  • I is the injected dose of antagonist
  • ID 50 is the dose of compound which inhibits 50% of specific radiotracer binding to O-GlcNAcase
  • NS is the amount of non-specifically bond radiotracer.
  • the compounds can be prepared using synthetic chemistry techniques well known in the art (see Comprehensive Heterocyclic Chemistry, Katritzky, A. R. and Rees, C. W. eds., Pergamon Press, Oxford, 1984) from a precursor of the compounds as outlined below.
  • the isotopically labeled compounds of this invention are prepared by incorporating the
  • isotopes e.g., into the substrate molecule.
  • a source of radioactivity such as a nuclear reactor, a cyclotron and the like.
  • isotopically labeled reagents such as 2 H 2 0, 3 H 3 CI, 14 C 6 H 5 Br, C1CH 2 14 C0C1 and the like, are commercially available.
  • the isotopically labeled reagents are then used in standard organic chemistry synthetic techniques to incorporate the isotope atom, or atoms, into a compound of the invention as described below.
  • the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature.
  • the present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I).
  • different isotopic forms of hydrogen (H) include protium (3 ⁇ 4), deuterium ( 2 H) and tritium ( 3 H). Protium is the predominant hydrogen isotope found in nature.
  • Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples.
  • Isotopically-enriched compounds within generic Formulas (I), (la), (lb), (II), (Ila) and (lib) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.
  • reaction mixture was concentrated under reduced pressure to give a residue, which was purified by Prep-HPLC under the following conditions [(Agilent 1200 prep HPLC): Column, SunFire Prep C18, 19 * 50 mm 5 um; mobile phase, water with 0.03% H4OH and CH3CN (10% CH3CN up to 45% in 10 min);
  • tert-butyl (3aR,5R,6S,7R,7aR)-6,7-bis(benzyloxy)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH- pyrano [3,2-d]thiazol-2-yl(methyl)carbamate A solution of tert-butyl (3aR,5R,6S,7R,7aR)-6,7- bis(benzyloxy)-5-((tert-butyldimethylsilyloxy)methyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2- d]thiazol-2-yl(methyl)carbamate (22 g, 35 mmol) in THF (200 mL) was treated with TBAF (18.4 g, 70 mmol) at room temperature for 4 hours.
  • reaction was quenched by H 2 0 (500 mL), and extracted with ethyl acetate (3x200 mL). The combined organic layer was washed with brine (2x150 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • tert-butyl (3aR,5R,6S,7R,7aR)-6,7-bis(benzyloxy)-5-((R)-2,2,2-trifluoro-l-hydroxyethyl)- 5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazol-2-yl(methyl)carbamate A mixture of TBAF (3.2 g, 12 mmol) and 4A molecule sieves (3.2 g) in THF (50 mL) was stirred for 30 min at 0°C, and followed by addition of crude tert-butyl (3aR,5S,6S,7R,7aR)-6,7-bis(benzyloxy)-5-formyl- 5,6,7,7a-tetrahydro-3aH-pyrano[3,2-d]thiazol-2-yl(methyl)carbamate and TMS-CF 3 (22.1 g, 155 mmol) in THF (100 m
  • H 3 P0 2 (515 mg, 7.8 mmol) and Cu 2 0 (14 mg, 0.1 mmol) were added to the reaction mixture. After additional 1 hour at 5 °C, the reaction was quenched by the saturated aqueous Na 2 C0 3 (35 mL), and extracted with ethyl acetate (3x40 mL). The combined organic layer was washed with brine (3x20 mL), dried over anhydrous magnesium sulfate and concentrated under vacuum.
  • tert-butyl (3aR,5R,6S,7R,7aR)-6,7-bis(allyloxy)-5-(hydroxymethyl)-5,6,7,7a-tetrahydro-3aH- pyrano[3,2-d]thiazol-2-yl(methyl)carbamate A solution of tert-butyl (3aR,5R,6S,7R,7aR)-6,7- bis(allyloxy)-5-((tert-butyldimethylsilyloxy)methyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2- d]thiazol-2-yl(methyl)carbamate (104 g, 197 mmol) in THF (700 mL) was treated with TBAF (77 g, 296 mmol) at 20°C for 6 hours, then the reaction was quenched by water (500 mL), extracted with ethyl acetate (5x300 mL).
  • reaction mixture was adjusted to acidic (pH at 3) with hydrochloric acid, and then extracted with dichloromethane (3 x 20 mL).
  • dichloromethane 3 x 20 mL
  • the combined organic layers were dried over anhydrous sodium sulfate and concentrated under vacuum to provide a residue , which was purified by a silica gel column, eluted with 20-50% ethyl acetate in petroleum ether to give the title compound as a white solid (600 mg, 58%).
  • Step 1 Synthesis of [1 lC]iodomethane.
  • [1 lC]C02 was produced using a Siemens RDS-111 cyclotron and the [ n C]C0 2 was converted to [ n C]MeI using a GE Medical Systems TRACERlab FCX system.
  • Step 2 [1 lC]MeI (from Step 1, 297 mCi) was trapped in a 0 °C mixture of (3aR,5S,6S,7R,7aR)- 2-(dimethylamino)-5-((R)-2,2,2-trifluoro-l-hydroxyethyl)-5,6,7,7a-tetrahydro-3aH-pyrano[3,2- d]thiazole-6,7-diol (0.42 mg) in DMF (0.25 mL) containing 1 ⁇ of KHMDS (1 M in THF). The reaction mixture was transferred to a 2 mL v-vial at 90°C, heated for 5 minutes, diluted with 3 ⁇ 40
  • the reaction mixture was transferred to a 2 mL v-vial at 70°C, heated for 5 minutes, diluted with H2O (0.8 mL) and injected onto the HPLC (XBridge CI 8, 10 X 150 mm, Waters).
  • the mobile phase consisted of acetonitrile (CH 3 CN) (A) and 0.1% ammonium hydroxide (pH 10) (B).
  • the solvent system started with 35% A and 65% B for 0-8 min at 3 mL/min, and then a gradient method was followed. A linear gradient of 35% A to 60% A over 6 min, holding at 60% A for 10 min with a run time of 25 min at 3 mL/min was used.
  • the preparative run was monitored at 254 nm with an Amersham Bioscience (Piscataway, NJ) UV-M II detector and a Bioscan (Missisauga, Ontario, Canada) FlowCount radioactivity detector.
  • the reaction mixture was transferred to a 2 mL v-vial at 90°C, heated for 4 minutes. The reaction mixture was allowed to cool for 2 min. Hydrogen chloride (400
  • the mobile phase consisted of acetonitrile (CH 3 CN) (A) and 0.1% ammonium hydroxide (pH 10) (B). A linear gradient of 30% A 70%B to 90% A 10% B over 15 min at 3 mL/min was used.
  • the production of fluorescent product was measured every 60 sec for 45 min with a Tecan Infinite M200 plate-reader with excitation at 355nM and emission detected at 460nM, with 4-Methylumbelliferone (Sigma M1381) used to produce a standard curve.
  • the slope of product production was determined for each concentration of compound tested and plotted, using standard curve fitting algorithms for sigmoidal dose response curves. The values for a four parameter logistic curve fit of the data was determined.
  • Ki values were determined using the Cheng-Prusoff equation; the Km of O- GlcNAcase for substrate was 0.2 mM. Examples 1 to 120 were tested in the above described assay and exhibited 3 ⁇ 4 values for inhibition of O-GlcNAcase in the range 0.1 nM-10 ⁇ .
  • Example 117 is a synthetic intermediate and does not possess inhibitory activity in the aforementioned range.
  • O-GlcNAcase which removes O-GlcNAc from cellular proteins, results in an increase in the level of O-GlcNAcylated protein in cells.
  • An increase in O- GlcNAcylated protein can be measured by an antibody, such as RL-2, that binds to O- GlcNAcylated protein.
  • the amount of O-GlcNAcylated protein:RL2 antibody interaction can be measured by enzyme linked immunosorbant assay (ELISA) procedures.
  • tissue culture cell lines expressing endogenous levels of O- GlcNAcase, can be utilized; examples include rat PC-12, and human U-87, or SK-N-SH cells.
  • rat PC-12 cells were plated in 96-well plates with approximately 10,000 cells / well.
  • Compounds to be tested were dissolved in DMSO, either 2 or 10 mM stock solution, and then diluted with DMSO and water in a two-step process using a Tecan workstation. Cells were treated with diluted compounds for 24 hours (5.4 ⁇ into 200 ⁇ .
  • the ELISA portion of the assay was performed in a black Maxisorp 96-well plate that was coated overnight at 4°C with 100 ⁇ , /well of the cell lysate (1 : 10 dilution of the lysate with PBS containing protease inhibitors, phosphatase inhibitors, and PMSF. The following day the wells were washed 3 times with 300 ⁇ , /well of Wash buffer (Tris-buffered saline with 0.1% Tween 20). The wells were blocked with 100 ⁇ , /well Blocking buffer (Tris buffered saline w/0.05% Tween 20 and 2.5% Bovine serum albumin). Each well was then washed two times with 300 ul/well of wash buffer.
  • the anti O-GlcNAc antibody RL-2 (Abeam, Cambridge, MA), diluted 1 : 1000 in blocking buffer, was added at 100 ⁇ /well. The plate was sealed and incubated at 37°C for 2 hr with gentle shaking. The wells were then washed 3 -times with 300 ⁇ /well wash buffer. To detect the amount of RL-2 bound horse-radish peroxidase (HRP) conjugated goat anti-mouse secondary antibody (diluted 1 :3000 in blocking buffer) was added at 100 ⁇ , /well. The plate was incubated for 60 min at 37°C with gentle shaking. Each well was then washed 3- times with 300 ⁇ /well wash buffer.
  • HRP horse-radish peroxidase
  • the detection reagent was added, 100 ⁇ , /well of Amplex Ultra RED reagent (prepared by adding 30 ⁇ of 10 mM Amplex Ultra Red stock solution to 10 ml PBS with 18 ⁇ , 3% hydrogen peroxide, H2O2). The detection reaction was incubated for 15 minutes at room temperature and then read with excitation at 530 nm and emission at 590 nm.
  • Amplex Ultra RED reagent prepared by adding 30 ⁇ of 10 mM Amplex Ultra Red stock solution to 10 ml PBS with 18 ⁇ , 3% hydrogen peroxide, H2O2.
  • LLC-PKl cells Bi-directional transport was evaluated in LLC-PKl cells in order to determine apparent permeability (P app ). LLC-PKl cells can form a tight monolayer and therefore can be used to assess vectorial transport of compounds from basolateral to apical (B— >A) and from apical to basolateral (A— » B).
  • P app was expressed as 10 "6 cm/s.
  • Table 4 shows O-GlcNAcase inhibitory activity and permeability for structurally similar compounds described in PCT/USl 1/059668
  • Table 4 shows O-GlcNAcase inhibitory activity and permeability for structurally similar compounds described in PCT/USl 1/059668

Abstract

L'invention concerne des composés de formule (I), chaque substituant de la formule (I) étant tel que défini dans la description, des formulations pharmaceutiques comprenant ces composés qui sont utiles en tant qu'inhibiteurs de N-acétylglucosaminidase à liaison O (O-GlcNAcase), et qui sont par conséquent utiles pour le traitement de certains troubles tels que la maladie d'Alzheimer, y compris la réduction des NFT et/ou de tau hyperphosphorylé. L'invention concerne également l'utilisation des composés en tant qu'agents d'imagerie O-GlcNAcase.
PCT/CN2012/075185 2012-05-08 2012-05-08 Inhibiteurs de glycosidase perméables et leurs utilisations WO2013166654A1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PCT/CN2012/075185 WO2013166654A1 (fr) 2012-05-08 2012-05-08 Inhibiteurs de glycosidase perméables et leurs utilisations
EP13787989.6A EP2847199B1 (fr) 2012-05-08 2013-05-03 Inhibiteurs de glycosidase perméables et leurs utilisations
CN201380023214.4A CN104395323B (zh) 2012-05-08 2013-05-03 可透过性糖苷酶抑制剂及其用途
KR1020147031131A KR102108586B1 (ko) 2012-05-08 2013-05-03 투과성 글리코시다제 억제제 및 그의 용도
CA2871920A CA2871920C (fr) 2012-05-08 2013-05-03 Inhibiteurs de glycosidase permeables et leurs utilisations
RU2014149183A RU2707292C2 (ru) 2012-05-08 2013-05-03 Проницаемые ингибиторы гликозидазы и их применения
PCT/US2013/039377 WO2013169576A1 (fr) 2012-05-08 2013-05-03 Inhibiteurs de glycosidase perméables et leurs utilisations
JP2015511546A JP6178843B2 (ja) 2012-05-08 2013-05-03 透過性グリコシダーゼインヒビターおよびその用途
US14/399,146 US9611275B2 (en) 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof
BR112014027724-9A BR112014027724B1 (pt) 2012-05-08 2013-05-03 Composto, e, composição farmacêutica
AU2013259892A AU2013259892B2 (en) 2012-05-08 2013-05-03 Permeable glycosidase inhibitors and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2012/075185 WO2013166654A1 (fr) 2012-05-08 2012-05-08 Inhibiteurs de glycosidase perméables et leurs utilisations

Publications (1)

Publication Number Publication Date
WO2013166654A1 true WO2013166654A1 (fr) 2013-11-14

Family

ID=49550060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2012/075185 WO2013166654A1 (fr) 2012-05-08 2012-05-08 Inhibiteurs de glycosidase perméables et leurs utilisations

Country Status (1)

Country Link
WO (1) WO2013166654A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104961781A (zh) * 2015-06-04 2015-10-07 淮海工学院 2-脱氧-2-异硫氰酸酯-1,3,4,6-四-O-苄基-β-D-吡喃葡萄糖及合成方法与用途
DE202014011287U1 (de) 2013-06-11 2019-02-06 The President And Fellows Of Harvard College SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025170A1 (fr) * 2006-08-31 2008-03-06 Simon Fraser University Inhibiteurs sélectifs de glycosidases et leurs utilisations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008025170A1 (fr) * 2006-08-31 2008-03-06 Simon Fraser University Inhibiteurs sélectifs de glycosidases et leurs utilisations

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202014011287U1 (de) 2013-06-11 2019-02-06 The President And Fellows Of Harvard College SC-ß Zellen und Zusammensetzungen zur Erzeugung der Zellen
EP3569694A1 (fr) 2013-06-11 2019-11-20 President and Fellows of Harvard College Cellules sc-beta et compositions et procédés pour les générer
CN104961781A (zh) * 2015-06-04 2015-10-07 淮海工学院 2-脱氧-2-异硫氰酸酯-1,3,4,6-四-O-苄基-β-D-吡喃葡萄糖及合成方法与用途

Similar Documents

Publication Publication Date Title
AU2013259892B2 (en) Permeable glycosidase inhibitors and uses thereof
AU2012276257B2 (en) Selective glycosidase inhibitors and uses thereof
AU2016202186B2 (en) Selective glycosidase inhibitors and uses thereof
AU2011349021B2 (en) Selective glycosidase inhibitors and uses thereof
RU2672873C2 (ru) Ингибиторы гликозидаз и их применения
WO2012061972A1 (fr) Inhibiteurs sélectifs de la glycosidase et ses utilisations
WO2014100934A1 (fr) Inhibiteurs de glycosidases et leurs utilisations
US8901087B2 (en) Selective glycosidase inhibitors and uses thereof
WO2013166654A1 (fr) Inhibiteurs de glycosidase perméables et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12876311

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12876311

Country of ref document: EP

Kind code of ref document: A1